ABBV

Historical Earnings Track Record for ABBV

AbbVie has reported earnings above the official consensus in seven of the last eight quarters, a beat rate of 7/8 or 88%. Over that same window, the average earnings surprise is -0.9%, which tells you that a small number of larger misses earlier in the sequence offset much of the positive beat skew from recent reports. The broader post-earnings tendency is a mild upward drift: the average 5-day price move in the five trading days after earnings across those eight quarters is 0.92%, classified as “up.” That average drift, however, masks a lot of single-event noise.

The last four reported quarters, most recent first, all beat estimates. On 2026-07-31 ABBV delivered actual EPS of $3.65 versus an estimate of $3.61, a 1.1% surprise, yet the stock fell 1.68% the next day and recorded a null 0% change over the following five days. On 2026-04-29 the company posted $2.65 versus $2.59 (2.3% surprise), and the stock rose 3.64% the next day and 0.56% over the next five sessions. On 2026-02-04 ABBV reported $2.71 versus $2.65 (2.3% surprise), producing a 0.88% next-day gain and a 1.7% five-day gain. On 2025-10-31 the result was $1.86 versus $1.77 (5.1% surprise), but the stock fell 2.79% the next day before climbing 0.51% over the following five days. The takeaway is that beating the number has not guaranteed a positive immediate reaction; the market has sold the news even when EPS exceeded the consensus.

Options-Flow Dynamics Around the Next Earnings Date

ABBV’s next scheduled report is on 2026-10-30 before the open, with a consensus EPS estimate of $3.87. In the days before an event like this, near-dated option implied volatility usually expands as traders price in the possibility of a gap move. After the report, that same implied volatility typically compresses—often called post-earnings volatility crush—so the market’s real expectation is reflected in the price of the at-the-money straddle rather than in the headline EPS estimate alone. Because the historical beat rate is 88% and the five-day drift has averaged 0.92% to the upside, the options market can lean slightly toward call positioning, but that positioning can change quickly and does not override the possibility of a negative single-day reaction.

Current technical context matters for reading that flow. The stock is trading at $245.67, just above the 50-day EMA of $241.59, while RSI sits at 46.8, essentially neutral. Sector classification is Healthcare/Drug Manufacturers – General, a group where earnings reactions are often driven by drug-specific commentary, revenue guidance, and margin trends rather than EPS alone. A disciplined trader typically watches whether option skew is bidding calls over puts into the event, whether implied move pricing is expanding or contracting, and whether post-earnings flow starts to unwind immediately after the print rather than chase direction on the headline.

For a deeper look at how institutional analysts, options positioning, and post-earnings flow are aligning ahead of the next report, see the full institutional verdict on the ticker page.